Health & Fitness
Mon, October 25, 2010Sun, October 24, 2010Sat, October 23, 2010Fri, October 22, 2010Thu, October 21, 2010Wed, October 20, 2010Tue, October 19, 2010Mon, October 18, 2010Sun, October 17, 2010Sat, October 16, 2010Fri, October 15, 2010Thu, October 14, 2010Wed, October 13, 2010Tue, October 12, 2010Mon, October 11, 2010Sun, October 10, 2010Sat, October 9, 2010Fri, October 8, 2010Thu, October 7, 2010Wed, October 6, 2010Tue, October 5, 2010Mon, October 4, 2010Sun, October 3, 2010Fri, October 1, 2010Quidel to Hold Third Quarter 2010 Results Conference Call on October 27, 2010
Published in Health and Fitness on Wednesday, October 13th 2010 at 16:10 GMT by Market Wire
SAN DIEGO--([ BUSINESS WIRE ])--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, will release third quarter 2010 financial results after market close on Wednesday, October 27, 2010.
Following the release of results, Douglas Bryant, president and chief executive officer, and John M. Radak, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss those results and to answer questions.
To participate in the live call by telephone from the U.S., dial 866-804-6928, or from outside the U.S. dial 857-350-1674, and enter the pass code 57002201.
A live webcast of the call can be accessed at [ http://www.quidel.com ], and the website replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on October 27 by dialing 888-286-8010 from the U.S., or 617-801-6888 for international callers, and entering pass code 82884944.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the leading brand names QuickVue®, D3® Direct Detection and Thyretaina", Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including [ influenza ], [ respiratory syncytial virus ], Strep A, herpes, pregnancy, [ thyroid disease ] and [ fecal occult blood ]. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit [ www.quidel.com ] and Diagnostic Hybrids at [ www.dhiusa.com ].
